Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KKKDX
ADC Name
AU2023281032A1 ADC-2
Synonyms
AU2023281032A1 ADC-2
   Click to Show/Hide
Organization
GENEQUANTUM HEALTHCARE (SUZHOU)CO.,LTD[CN/CN]
Drug Status
Investigative
Drug-to-Antibody Ratio
3.8
Antibody Name
anti-TROP2 antibody
  Antibody Info 
Antigen Name
Tumor-associated calcium signal transducer 2 (TACSTD2)
  Antigen Info 
Payload Name
AU2023281032A1 ADC-3 Payload
  Payload Info 
Linker Name
AU2023281032A1 ADC-3 Linker
  Linker Info 
Conjugate Type
site-specific conjugation
Combination Type
LP-6
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
maximum killing percentage 
39
nM
CVCL_0419
Breast adenocarcinoma
maximum killing percentage 
59.29
nM
CVCL_1259
Breast ductal carcinoma
maximum killing percentage 
65.17
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.1076
nM
CVCL_0033
Breast adenocarcinoma
Half Maximal inhibitory Concentration (lC50) 
0.4355
nM
CVCL_1259
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 5 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data maximum killing percentage 39 nM Negative TROP2 expression ( TROP2-)
Method Description
the maximum killing percentage relative to the control group in MDA-MB-468
In Vitro Model Breast adenocarcinoma MDA-MB-468 cells CVCL_0419
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data maximum killing percentage 59.29 nM Positive TROP2 expression (TROP2 +++/++)
Method Description
the maximum killing percentage relative to the control group in HCC1954
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data maximum killing percentage 65.17 nM Positive TROP2 expression (TROP2 +++/++)
Method Description
the maximum killing percentage relative to the control group in SK-BR-3
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.1076 nM Positive TROP2 expression (TROP2 +++/++)
Method Description
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM) in SK-BR-3
In Vitro Model Breast adenocarcinoma SK-BR-3 cells CVCL_0033
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (lC50) 0.4355 nM Positive TROP2 expression (TROP2 +++/++)
Method Description
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM) in HCC1954
In Vitro Model Breast ductal carcinoma HCC1954 cells CVCL_1259
References
Ref 1 Oligosaccharide linker, linker-payload comprising the same and glycan chain-remodeled antibody-drug conjugate, preparation methods and uses thereof